Expression of Rho‐kinase and its functional role in the contractile activity of the mouse vas deferens
- 1 October 2003
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 140 (4) , 743-749
- https://doi.org/10.1038/sj.bjp.0705479
Abstract
The effects of two Rho-kinase inhibitors, Y-27632 and fasudil, were investigated on the contractions produced by electrical field stimulation (EFS, 40 V, 1 mS, 2, 4, 8 and 16 Hz, for 20 s), KCl (30 - 60 mm), phenylephrine (Phe) (10-5 - 10-4 m), adenosine-3', 5'-triphosphate (ATP) (10-4 - 10-3 m) and alpha,beta-methylene ATP (10-5 m). EFS produced frequency-dependent reproducible contractile activity, which was almost abolished by guanethidine (10-5 m, for 1 h). This contraction consisted of two components (a phasic initial contraction followed by a tonic one), and it was inhibited by Y-27632 and fasudil (both at 10-5 m). However, these inhibitors had no effect on resting tension of the tissue. Contractions elicited by KCl (30 - 60 mm) were insensitive to guanethidine (10-5 m, for 1 h), but suppressed by Y-27632 (10-5 m) and fasudil (10-5 m). In addition, the contractions induced by Phe (an alpha1-adrenoceptor agonist) and ATP (a purinergic agent) were inhibited significantly by Y-27632 (10-5 m). Phasic contractions evoked by the selective P2X purinoceptor agonist alpha,beta-methylene ATP were also suppressed by Y-27632 (10-5 m). Western blot analysis revealed that the mouse vas deferens expresses Rho-kinase (ROKalpha, ROCK-2 isoform) protein with a molecular weight of approximately 160 kDa. As a positive control, the presence of this protein was also shown in homogenates of smooth muscle from the rat mesenteric artery. In conclusion, Rho-kinase protein is expressed in the mouse vas deferens, and it mediates neurogenic contractile activity as well as the contractions induced by KCl, Phe, ATP and alpha,beta-methylene ATP. Owing to the suppressive effects of Rho-kinase inhibitors on the contractile activity of the vas deferens, the possibility that these compounds might impair ejaculation must be taken into account when considering them as potential agents in the treatment of erectile dysfunction.Keywords
This publication has 37 references indexed in Scilit:
- Expression and functional role of Rho‐kinase in rat urinary bladder smooth muscleBritish Journal of Pharmacology, 2003
- Regional variation in P2 receptor expression in the rat pulmonary arterial circulationBritish Journal of Pharmacology, 2002
- RhoA-mediated Ca2+ Sensitization in Erectile FunctionPublished by Elsevier ,2002
- Discrimination by SZL49 between contractions evoked by noradrenaline in longitudinal and circular muscle of human vas deferensBritish Journal of Pharmacology, 2002
- Y‐27632, an inhibitor of Rho‐kinase, antagonizes noradrenergic contractions in the rabbit and human penile corpus cavernosumBritish Journal of Pharmacology, 2001
- Inhibition of Rho‐associated kinase blocks agonist‐induced Ca2+ sensitization of myosin phosphorylation and force in guinea‐pig ileumThe Journal of Physiology, 2000
- Signal transduction by G‐proteins, Rho‐kinase and protein phosphatase to smooth muscle and non‐muscle myosin IIThe Journal of Physiology, 2000
- α1A-Adrenoceptor mediated contraction of rat prostatic vas deferens and the involvement of ryanodine stores and Ca2+influx stimulated by diacylglycerol and PKCBritish Journal of Pharmacology, 1998
- Signal transduction and regulation in smooth muscleNature, 1994
- The Function of Myosin and Myosin Light Chain Kinase Phosphorylation in Smooth MuscleAnnual Review of Pharmacology and Toxicology, 1985